A

Amgen

Makes biotech medicines for serious illnesses

Principal Information Systems Unix Architect

Full-TimeUpdated on 10/24/2026
$138.2k - $186.9k+ Discretionary annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, PhD, Associate's
Remote in USA
Remote
IT OperationsSystem Administration

About the job

Requirements
  • A doctorate degree and 2 years of relevant experience, or a master’s degree and 4 years of relevant experience, or a bachelor’s degree and 6 years of relevant experience, or an associate’s degree and 10 years of relevant experience, or a high school diploma or GED and 12 years of relevant experience.
  • Deep expertise in enterprise Linux architecture, including Red Hat Enterprise Linux, Ubuntu, or Amazon Linux; operating-system internals; system hardening; patching; upgrades; performance tuning; capacity management; reference architectures; technology roadmaps; and architecture principles and standards.
  • Strong Unix systems design and problem-solving skills, with the ability to independently lead major technical initiatives, establish architectural and engineering standards, and resolve complex cross-platform incidents.
  • A proven track record of designing, delivering, and supporting large-scale, highly available Unix and Linux platforms across physical, virtualized, and cloud environments, including clustering, disaster recovery, storage, networking, and service continuity.
  • Advanced automation and scripting expertise using Ansible, Python, Shell/Bash, infrastructure as code, source control, and CI/CD practices to standardize builds, eliminate configuration drift, and automate provisioning and operational tasks.
  • Demonstrated proficiency in AWS, Azure, or GCP infrastructure, virtualization, container platforms, enterprise monitoring, and security controls, with a strong understanding of resilient hybrid-cloud architecture and cost optimization.
  • The ability to provide principal-level technical leadership, mentor junior and mid-level engineers, communicate with technical and business stakeholders, and coordinate effectively during major incidents.
Responsibilities
  • Lead the end-to-end architecture, engineering, and lifecycle management of enterprise Unix and Linux platforms, from technical strategy and standards through deployment, operations, modernization, and retirement.
  • Act as the technical owner for large-scale Unix and Linux initiatives, driving architecture decisions, platform standardization, scalability, availability, resilience, and long-term maintainability.
  • Architect scalable Unix platforms across Amgen’s data centers, AWS, Azure, or GCP, integrating virtualization, supporting container orchestration, storage, networking, and enterprise management tooling.
  • Define and institutionalize architectural standards, validation controls, and governance frameworks for operating-system builds, configuration baselines, patching, vulnerability remediation, privileged access, audit readiness, and regulatory compliance.
  • Advise senior technical leadership, security teams, other architects, and business stakeholders by presenting architectural options and tradeoffs based on service requirements and platform capabilities. Influence and help the Unix service owner achieve measurable improvements in reliability, performance, observability, and operational efficiency.
  • Establish and enforce best practices in platform engineering, infrastructure as code, configuration management, and DevSecOps, and drive the platform architecture roadmap to improve automated provisioning, CI/CD, backup and recovery, configuration-drift control, Agentic AI, and cost optimization.
  • Drive capacity planning, performance engineering, and technology modernization, using workload trends, benchmarking, root-cause analysis, and controlled testing to improve system efficiency and reduce technical debt.
  • Provide technical leadership and mentorship to L4 and L5 engineers through architecture reviews, automation and script reviews, complex troubleshooting, operational readiness assessments, and technical guidance.
  • Lead cross-functional collaboration across Unix engineering, cloud, storage, network, database, middleware, cybersecurity, application, and service management teams to deliver integrated infrastructure solutions.
  • Stay current with advancements in Unix technologies, automation, cloud-native infrastructure, observability, and security, and lead the evaluation and adoption of technologies and architecture changes to improve platform resilience and supportability.
  • Provide major incident escalation leadership and complex problem resolution for Unix services, coordinating technical teams, restoring service, identifying root causes, and ensuring corrective actions prevent recurrence.
Desired Qualifications
  • A bachelor’s or master’s degree in computer science, information systems, engineering, or a related technical discipline.
  • Relevant industry certifications such as RHCE, AWS, Azure, or GCP.
  • Advanced experience with Ansible Automation Platform, Terraform, Puppet, or similar tools for enterprise-scale provisioning, configuration management, orchestration, and compliance automation.
  • Experience designing and maintaining standardized operating-system images, automated build pipelines, configuration-as-code repositories, and policy-based validation controls.
  • Experience with identity and access management, privileged access management, LDAP, Active Directory integration, Kerberos, certificates, and secrets management.
  • Knowledge of security and compliance frameworks such as CIS benchmarks, vulnerability management, audit controls, and automated remediation.
  • Working knowledge of enterprise middleware and database dependencies on Unix/Linux platforms, including performance, connectivity, patching, and startup or shutdown coordination.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.